Position in GH
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$10,997,199
New position
Shares Held
73,300
first reported quarter
Ownership
0.055%
of shares outstanding
% of Portfolio
0.62%
of 13F equity value
Holder Rank
#155
of 594 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026Catalyst Funds Management Pty Ltd holds $17,014,989 across 10 Diagnostics & Research names. GH ranks #1 (64.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GH |
Guardant Health, Inc.
This page
|
73,300 | $10,997,199 | |
| 2 | TMO |
Thermo Fisher Scientific Inc.
|
4,360 | $2,185,929 | |
| 3 | IDXX |
Idexx Laboratories Inc /De
|
1,821 | $958,647 | |
| 4 | ILMN |
Illumina, Inc.
|
4,200 | $738,486 | |
| 5 | VCYT |
Veracyte, Inc.
|
9,650 | $566,744 | |
| 6 | WAT |
Waters Corp /De/
|
1,360 | $510,054 | |
| 7 | IQV |
Iqvia Holdings Inc.
|
2,251 | $434,938 | |
| 8 | CRL |
Charles River Laboratories International, Inc.
|
950 | $215,450 |
All Filings in GH
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,997,199 | 73,300 | Shares | Sole | 2026-08-10 | |
| No filing history on record for this holder in this stock. | ||||||